Targeting Metalloproteins by Fragment‐Based Lead Discovery

It has been estimated that nearly one‐third of functional proteins contain a metal ion. These constitute a wide variety of possible drug targets including metalloproteinases, dehydrogenases, oxidoreductases, hydrolases, deacetylases, or many others in which the metal ion is either of catalytic or of structural nature. Despite the predominant role of a metal ion in so many classes of drug targets, current high‐throughput screening techniques do not usually produce viable hits against these proteins, likely due to the lack of proper metal‐binding pharmacophores in the current screening libraries. Herein, we describe a novel fragment‐based drug discovery approach using a metal‐targeting fragment library that is based on a variety of distinct classes of metal‐binding groups designed to reliably anchor the fragments at the target’s metal ions. We show that the approach can effectively identify novel, potent and selective agents that can be readily developed into metalloprotein‐targeted therapeutics.

[1]  Seth M Cohen,et al.  Identifying chelators for metalloprotein inhibitors using a fragment-based approach. , 2011, Journal of medicinal chemistry.

[2]  A. Strongin,et al.  Biochemical Characterization of the Cellular Glycosylphosphatidylinositol-linked Membrane Type-6 Matrix Metalloproteinase* , 2010, The Journal of Biological Chemistry.

[3]  Seth M. Cohen,et al.  Chelator Fragment Libraries for Targeting Metalloproteinases , 2010, ChemMedChem.

[4]  Wendy A. Warr,et al.  Fragment-based drug discovery , 2009, J. Comput. Aided Mol. Des..

[5]  M. Rowley,et al.  Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model. , 2009, Bioorganic & medicinal chemistry letters.

[6]  M. Pellecchia,et al.  Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors. , 2009, Bioorganic & medicinal chemistry.

[7]  Yuchen Cao,et al.  Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship. , 2009, Bioorganic & medicinal chemistry letters.

[8]  B. Shoichet,et al.  Molecular docking and ligand specificity in fragment-based inhibitor discovery. , 2009, Nature chemical biology.

[9]  Brett A Tounge,et al.  Ligand efficiency and fragment-based drug discovery. , 2009, Drug discovery today.

[10]  J Andrew McCammon,et al.  Thioamide hydroxypyrothiones supersede amide hydroxypyrothiones in potency against anthrax lethal factor. , 2009, Journal of medicinal chemistry.

[11]  Harald Schwalbe,et al.  Perspectives on NMR in drug discovery: a technique comes of age , 2008, Nature Reviews Drug Discovery.

[12]  Seth M Cohen,et al.  Zinc‐Binding Groups Modulate Selective Inhibition of MMPs , 2008, ChemMedChem.

[13]  Jong Yup Kim,et al.  Convenient Total Synthesis of Taranabant (MK-0364), a Novel Cannabinoid-1 Receptor Inverse Agonist as an anti-Obesity Agent. , 2008 .

[14]  A. Strongin,et al.  Rhodanine Derivatives as Selective Protease Inhibitors Against Bacterial Toxins , 2008, Chemical biology & drug design.

[15]  A. Osterman,et al.  Glycerate 2-Kinase of Thermotoga maritima and Genomic Reconstruction of Related Metabolic Pathways , 2007, Journal of bacteriology.

[16]  D. Fattori,et al.  Fragment-Based Approach to Drug Lead Discovery , 2008, Drugs in R&D.

[17]  C. Meier,et al.  A New Short and Efficient Synthetic Route to C8-N-Acetylarylamine 2'-Deoxyguanosine Phosphoramidites , 2007 .

[18]  Jan Schultz,et al.  Integration of fragment screening and library design. , 2007, Drug discovery today.

[19]  Glyn Williams,et al.  Fragment-based screening using X-ray crystallography and NMR spectroscopy. , 2007, Current opinion in chemical biology.

[20]  A. Kral,et al.  Design of novel histone deacetylase inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[21]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[22]  Seth M Cohen,et al.  The Design of Inhibitors for Medicinally Relevant Metalloproteins , 2007, ChemMedChem.

[23]  M. Pellecchia,et al.  A high-throughput screening approach to anthrax lethal factor inhibition. , 2006, Bioorganic chemistry.

[24]  B. Déprez,et al.  A library of novel hydroxamic acids targeting the metallo-protease family: design, parallel synthesis and screening. , 2007, Bioorganic & medicinal chemistry.

[25]  Maurizio Pellecchia,et al.  Structure–activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting Bid , 2006, Proceedings of the National Academy of Sciences.

[26]  A. Khlebnikov,et al.  Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening. , 2006, Journal of medicinal chemistry.

[27]  M. Uttamchandani,et al.  Rapid assembly of matrix metalloprotease inhibitors using click chemistry. , 2006, Organic letters.

[28]  Seth M Cohen,et al.  A new role for old ligands: discerning chelators for zinc metalloproteinases. , 2006, Journal of the American Chemical Society.

[29]  H. Mori,et al.  Complete set of ORF clones of Escherichia coli ASKA library (a complete set of E. coli K-12 ORF archive): unique resources for biological research. , 2006, DNA research : an international journal for rapid publication of reports on genes and genomes.

[30]  D. Crick,et al.  1-Deoxy-d-Xylulose 5-Phosphate Reductoisomerase (IspC) from Mycobacterium tuberculosis: towards Understanding Mycobacterial Resistance to Fosmidomycin , 2005, Journal of bacteriology.

[31]  John A. Young,et al.  Receptor-specific requirements for anthrax toxin delivery into cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Edgar Jacoby,et al.  Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.

[33]  Steve Price,et al.  Solid-phase synthesis of N-formylhydroxylamines (reverse/retro-hydroxamates). , 2005, Organic letters.

[34]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[35]  E. Scolnick,et al.  Anthrax lethal factor inhibition , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Phillip Gribbon,et al.  High-throughput drug discovery: what can we expect from HTS? , 2005, Drug discovery today.

[37]  Daniel Delorme,et al.  Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation. , 2003, Current medicinal chemistry.

[38]  K. Glaser,et al.  Histone deacetylase inhibitors: the Abbott experience. , 2003, Current medicinal chemistry.

[39]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[40]  G. Giacomelli,et al.  Simple one-flask method for the preparation of hydroxamic acids. , 2003, Organic letters.

[41]  Jordi Mestres,et al.  Identification of "latent hits" in compound screening collections. , 2003, Journal of medicinal chemistry.

[42]  John Ellingboe,et al.  Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. , 2003, Journal of medicinal chemistry.

[43]  Yan Guo,et al.  NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability. , 2002, Journal of medicinal chemistry.

[44]  S. Schreiber,et al.  Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. , 2001, Organic letters.

[45]  G. Ciszewski,et al.  Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases. , 2001, Journal of medicinal chemistry.

[46]  S. Davidsen,et al.  Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors. , 2001, Bioorganic & medicinal chemistry letters.

[47]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[48]  C. Supuran,et al.  Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. , 2000, Journal of medicinal chemistry.

[49]  Shunji Takahashi,et al.  Characterization of 1-Deoxy-d-xylulose 5-Phosphate Reductoisomerase, an Enzyme Involved in Isopentenyl Diphosphate Biosynthesis, and Identification of Its Catalytic Amino Acid Residues* , 2000, The Journal of Biological Chemistry.

[50]  I. Kuntz,et al.  The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Shunji Takahashi,et al.  Fosmidomycin, a specific inhibitor of 1-deoxy-d-xylulose 5-phosphate reductoisomerase in the nonmevalonate pathway for terpenoid biosynthesis , 1998 .

[52]  A. Butler,et al.  Acquisition and utilization of transition metal ions by marine organisms. , 1998, Science.

[53]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[54]  R. D. Dyer,et al.  Hydroxamic acid inhibitors of 5-lipoxygenase. , 1987, Journal of medicinal chemistry.

[55]  J. Clemens,et al.  Synthesis of D-oxa tricyclic partial ergolines as dopamine agonists. , 1987, Journal of medicinal chemistry.

[56]  M. D. Corbett,et al.  Reaction of nitroso aromatics with glyoxylic acid. A new path to hydroxamic acids , 1980 .